Testosterone (T) deficiency and erectile dysfunction (ED) are independently functionally and socially impairing, and their concurrence in men can be challenging to treat. Successful management requires an understanding of the mechanisms through which T underlies normal erectile function. While the literature elucidating some of these mechanisms is vast (e.g., androgen regulation of the activity of nitric oxygen synthase and phosphodiesterase type 5) for others it is scarce (e.g., catalysts of castration-induced corporal fibrosis). The randomized controlled trial data for the efficacy of T replacement as mono- or combination therapy to treat ED has been conflicting. Positive results were frequently not clinically meaningful. Meta-analyses have been helpful in illuminating trends that seem to be promising. Consensus is still lacking in several areas, such as the threshold of low T severity for which replacement therapy is most beneficial; the timing for initiating combination therapy; and the duration of treatment.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest. 1966;45:301–13.
Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172:1399–403.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724–31.
Kang S, Park HJ, Park NC. Serum total testosterone level and identification of late-onset hypogonadism: a community-based study. Korean J Urol. 2013;54:619–23.
Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry. 2005;66:7–14.
Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl J Med. 2010;363:123–35.
Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503–10.
Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66:1090–9.
Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18:20–4.
Brock G, Heiselman D, Maggi M, Kim SW, Rodr íguez VJM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699–705.
McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13:135–43.
Ansong KS, Lewis C, Jenkins P, Bell J. Epidemiology of erectile dysfunction: a community-based study in rural New York state. Ann Epidemiol. 2000;10:293–6.
Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;25:1458–63.
Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61:2019–25.
El-Sakka AI. Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol. 2006;49:564–9.
Cheng JYW, Ng EML, Chen RYL, Ko JSN. Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19:343–52.
Zhao S, Deng T, Luo L, Wang J, Li E, Liu L, et al. Association between opioid use and risk of erectile dysfunction: a systematic review and meta-analysis. J Sex Med. 2017;14:1209–19.
Kalka D, Domagala ZA, Kowalewski P, Rusiecki L, Koleda P, Marciniak W, et al. Effect of endurance cardiovascular training intensity on erectile dysfunction severity in men with ischemic heart disease. Am J Mens Health. 2015;9:360–9.
Banner LL, Anderson RU. Original research—psychology: integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med. 2007;4:1117–25.
Chen L, Staubli SEL, Schneider MP, Kessels AG, Ivic S, Bachmann LM, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68:674–80.
Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the ams 700cx inflatable penile prosthesis: results of a long-term multicenter study. J Urol. 2000;164:376–80.
Baba K, Yajima M, Carrier S, Akkus E, Reman J, Nunes L, et al. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology 2000;56:533–8.
Hosogai N, Takakura S, Manda T, Mutoh S. Enzyme activities of the nitric oxide–cGMP pathway in corpus cavernosum isolated from middle-aged rats. Eur J Pharm. 2003;473:65–70.
Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl. 1997;18:110–5.
Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861–8.
Armagan A, Kim NN, Goldstein I, Traish AM. Dose—response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl. 2006;27:517–26.
Park KH, Kim SW, Kim KD, Paick J-S. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999;83:327–33.
Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes1. Biol Reprod. 1999;61:1012–6.
Mills TM, Lewis RW, Stopper VS. Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod. 1998;59:1413–8.
Dai YT, Stopper V, Lewis R, Mills T. Effects of castration and testosterone replacement on veno-occlusion during penile erection in the rat. Asian J Androl. 1999;1:53–9.
Zhang X, Kuppam D, Melman A, Disanto M. The sphingosine-1-phosphate synthetic analogue fingolimod (FTY-720-P) potently modulates rat and human corpus cavernosum smooth muscle tone via the S1P3 receptor both in vitro and in vivo. J Sex Med. 2010;7:7–8.
Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoA-mediated Ca2+ sensitization in erectile function*. J Biol Chem. 2002;277:30614–21.
Yin J, Guo Y, Chen P, Xiao H, Wang X, DiSanto ME, et al. Testosterone regulates the expression and functional activity of sphingosine-1-phosphate receptors in the rat corpus cavernosum. J Cell Mol Med. 2018;22:1507–16.
Keast JR, Gleeson RJ, Shulkes A, Morris MJ. Maturational and maintenance effects of testosterone on terminal axon density and neuropeptide expression in the rat vas deferens. Neuroscience 2002;112:391–8.
Armagan A, Hatsushi K, Toselli P. The effects of testosterone deficiency on the structural integrity of the penile dorsal nerve in the rat. Int J Impot Res. 2008;20:73–8.
Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253–63.
Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5a dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661–6.
Parshad O, Stevens MC, Preece MA, Thomas PW, Serjeant GR. The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J 1994;43:12–4.
Musicki B, Karakus S, Akakpo W, Silva FH, Liu J, Chen H, et al. Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates pde5 expression and enos activity in the penis. Andrology. 2018;6:184–91.
Zhang XH, Hu LQ, Zheng XM, Li SW. Apoptosis in rat erectile tissue induced by castration. Asian J Androl. 1999;1:181–5.
Tomada I, Tomada N, Almeida H, Neves D. Androgen depletion in humans leads to cavernous tissue reorganization and upregulation of Sirt1-eNOS axis. Age Dordr Neth. 2013;35:35–47.
Wang X-J, Xu T-Y, Xia L-L, Zhong S, Zhang X-H, Zhu Z-W, et al. Castration impairs erectile organ structure and function by inhibiting autophagy and promoting apoptosis of corpus cavernosum smooth muscle cells in rats. Int Urol Nephrol. 2015;47:1105–15.
Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(Jan):285–90.
Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int. 2003;91:830–8.
Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie’s plaque fibroblasts. J Urol. 2008;179:2447–55.
Cui K, Li R, Chen R, Li M, Wang T, Yang J, et al. Androgen deficiency impairs erectile function in rats through promotion of corporal fibrosis. Andrologia. 2018;50.
Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the international index of erectile function scale. Eur Urol. 2011;60:1010–6.
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N. Engl J Med. 2016;374:611–24.
Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381–94.
Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20–8.
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72:1000–11.
Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 2015;314:570.
Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–6.
Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763–71.
Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57:1141–4.
Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction. Ann Intern Med. 2012;157:681–91.
Shabsigh R, Kaufman JM, Steidle C, Padma -Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–63.
Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284–93.
Park MG, Yeo JK, Cho D, Kim JW, Kim JW, Oh MM, et al. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med. 2015;12:966–74.
Zhu J, Zhang W, Ou N, Song Y, Kang J, Liang Z, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl Androl Urol. 2020;9:59100–600.
Bancroft J, Wu FCW. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983;12:59–66.
Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men*. J Clin Endocrinol Metab. 1983;57:557–62.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Onyeji, I.C., Clavijo, R.I. Testosterone replacement therapy and erectile dysfunction. Int J Impot Res 34, 698–703 (2022). https://doi.org/10.1038/s41443-021-00512-w